Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016
- PMID: 29801111
- PMCID: PMC6145721
- DOI: 10.1001/jamaoncol.2018.0610
Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016
Abstract
This data analysis examines the fulfillment of postmarketing requirements associated with drugs granted accelerated approval for oncology indications in the past 6 years.
Conflict of interest statement
Comment in
-
Reinforcing the social compromise of accelerated approval.Nat Rev Clin Oncol. 2018 Oct;15(10):596-597. doi: 10.1038/s41571-018-0066-3. Nat Rev Clin Oncol. 2018. PMID: 29970919 No abstract available.
References
-
- Jena AB, Zhang J, Lakdawalla DN. The trade-off between speed and safety in drug approvals. JAMA Oncol. 2017;3(11):1465-1466. - PubMed
-
- Woloshin S, Schwartz LM, White B, Moore TJ. The fate of FDA postapproval studies. N Engl J Med. 2017;377(12):1114-1117. - PubMed
-
- US Government Accountability Office DRUG SAFETY: FDA Expedites Many Applications, But Data for Postapproval Oversight Need Improvement (GAO-16-192: Published December 15, 2015. Publicly released January 14, 2016) https://www.gao.gov/products/GAO-16-192. Accessed February 27, 2018.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
